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Delayed bactericidal response of Mycobacterium
tuberculosis to bedaquiline involves remodelling
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Bedaquiline (BDQ), an ATP synthase inhibitor, is the ﬁrst drug to be approved for treatment of
multidrug-resistant tuberculosis in decades. Though BDQ has shown excellent efﬁcacy in
clinical trials, its early bactericidal activity during the ﬁrst week of chemotherapy is minimal.
Here, using microﬂuidic devices and time-lapse microscopy of Mycobacterium tuberculosis, we
conﬁrm the absence of signiﬁcant bacteriolytic activity during the ﬁrst 3–4 days of exposure
to BDQ. BDQ-induced inhibition of ATP synthesis leads to bacteriostasis within hours after
drug addition. Transcriptional and proteomic analyses reveal that M. tuberculosis responds to
BDQ by induction of the dormancy regulon and activation of ATP-generating pathways,
thereby maintaining bacterial viability during initial drug exposure. BDQ-induced bacterial
killing is signiﬁcantly enhanced when the mycobacteria are grown on non-fermentable energy
sources such as lipids (impeding ATP synthesis via glycolysis). Our results show that BDQ
exposure triggers a metabolic remodelling in mycobacteria, thereby enabling transient
bacterial survival.
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T
uberculosis (TB) still claims more human lives each year
than any other bacterial infection1. The latest report from
the World Health Organization revealed signs of progress
against drug-susceptible TB; however, the incidence rates of
multidrug-resistant TB (MDR-TB) have sharply increased,
thereby threatening global TB control programs1,2. Recent
clinical data from two controlled phase 2 trials have revealed
the efﬁcacy of a novel anti-TB drug, bedaquiline (BDQ, marketed
as Sirturo), in treatment of MDR-TB3,4. On the basis of the
surrogate end point of time-to-sputum culture conversion, BDQ
was granted accelerated approval by the US Food & Drug
Administration for the treatment of pulmonary MDR-TB as part
of combination therapy in adults5,6. This marks the ﬁrst
regulatory approval of an anti-TB drug since the introduction
of rifampin in 1971. BDQ is a ﬁrst-in-class ATP synthase
inhibitor, displaying high selectivity for mycobacterial
ATP synthase7–9, thus highlighting the key role of energy
metabolism as a novel drug target pathway in mycobacteria10–12.
BDQ exhibited potent bactericidal activity both in mouse
models of TB infection7, and also when given for either 2 or 6
months in combination with a background regimen in MDR-TB
patients3,4. However, its bactericidal activity in extended early
bactericidal activity (eBA) studies showed a delayed onset, with
the decline in bacterial sputum counts observed only from day
4–6 onwards13–15. This delay in onset of bactericidal activity is
not simply due to the inability of the drug to reach steady state
levels in patients, as a similar delay was seen in in vitro studies7,16.
Similar to BDQ, the front-line anti-TB drug pyrazinamide also
displays almost no bactericidal activity during the ﬁrst 2–4 days
of treatment, but nonetheless it kills consistently thereafter12.
However, pyrazinamide was developed in 1950s in a different
regulatory environment. Today, eBA is used for establishing a
quick clinical proof of concept, and unfavourable eBA is regarded
as an impediment for drug development. eBA studies are
traditionally carried out over a period of 2–7 days, con-
sequently eBA may underestimate the potency of drugs with a
delayed onset of bactericidal activity. As such, insight into
microbiological and molecular factors underlying the delayed
onset of bactericidal activity by BDQ may provide valuable
information for the design and interpretation of eBA studies on
new drug candidates.
In the current report, we aim at understanding the reason for the
delayed onset of killing by BDQ. We investigate individual cells of
M. tuberculosis in microﬂuidic devices and show the absence of
bacteriolysis in mycobacteria during the initial days of BDQ
treatment. We employ multiple biochemical and molecular
approaches and elucidate temporal changes in bacterial metabolic
pathways upon BDQ exposure. We show bacteria tend to minimize
the consumption of cellular ATP and at same time enhance the
capacity of ATP-generating pathways, which contributes to
maintaining bacterial viability in spite of antibiotic stress. We also
investigate the impact of the employed energy source on
mycobacterial susceptibility to BDQ and demonstrate that myco-
bacteria grown on lipids display enhanced BDQ mediated killing.
These data reveal how metabolic remodeling upon drug
exposure can enable transient bacterial survival. Our results also
indicate that inhibitors of mycobacterial ATP synthesis may
prove powerful drugs for eradicating mycobacteria growing in
lipid-rich environments in the human host. This shows that non-
fermentable energy sources can be explored for in vitro
characterization of new molecules targeting mycobacterial energy
pathways. Finally, these data highlight that drugs speciﬁcally
targeting the mycobacterial respiratory chain components like
ATP synthase or cytochrome bc1, may exhibit a delayed onset of
bactericidal activity both in vitro as well as in clinical eBA type
studies within TB patients.
Results
Delayed killing of M. tuberculosis by BDQ. We correlated the
killing activity of BDQ with its impact on cellular ATP levels, in
particular during the initial days of drug exposure. We conﬁrmed
that BDQ was highly bactericidal on M. tuberculosis over a period
of 18 days in vitro, leading to a drop ofB4 log10 units in colony
forming units (CFUs) by day 14 (Fig. 1a). However, during the
ﬁrst 2 days BDQ showed very little bactericidal activity, with
o1 log10 unit of killing observed by day 4, even at 300 minimal
inhibitory concentration (MIC) (MIC99 of BDQ is 0.03 mgml 1)7
(Fig. 1b). Simultaneous measurements of bacterial ATP levels
revealed a 1,000-fold drop in cellular ATP levels by day 9 at
300 MIC (Fig. 1c). Nevertheless, during the ﬁrst 2 days of
BDQ exposure o10-fold drop in ATP levels was observed at
300 MIC, with minimal changes at drug concentrations of 3 or
30 MIC (Fig. 1d). As a control, isoniazid a potent inhibitor
of cell envelope lipid biosynthesis had no effect on ATP levels,
even at 300 MIC (Fig. 1c,d). Moreover, a BDQ-resistant
M. tuberculosis strain carrying point mutations in ATP synthase7
did not show any decrease in ATP levels at all drug
concentrations tested, demonstrating target speciﬁcity (Fig. 1d,
inset). ATP synthase is essential for growth in mycobacteria17,18
and its inhibition by BDQ efﬁciently shuts down the function of
this key metabolic enzyme. However, the decrease in ATP levels
observed during the initial 2-day period of BDQ exposure did not
sufﬁciently interfere with bacterial viability (Fig. 1b,d), suggesting
that, at the population level, ATP levels need to be reduced by
more than 1 log10 unit before signiﬁcant killing starts. Consistent
with this result, previously it has been shown that dormant
M. tuberculosis cultures are viable with B10-fold lower ATP
levels as compared with replicating bacteria, but are efﬁciently
killed upon further ATP depletion19.
Single-cell analysis of the effect of BDQ on M. tuberculosis. It is
possible that the delayed onset of bacterial killing is due to the
ability of the bacterial population or a subset of the population
to continue growing and dividing using either stored ATP
resources or by surviving on the depleted ATP levels. To address
this issue, we studied the effect of BDQ on M. tuberculosis using
time-lapse imaging of individual bacteria grown in microﬂuidic
devices.
In the presence of BDQ at 300 MIC cell lysis was not
observed until 3–4 days after drug addition (Fig. 2a,
Supplementary Movie 1), consistent with the lack of bactericidal
activity observed in our in vitro kill kinetics assays. However,
BDQ addition resulted in decrease of the bacterial growth rate
within 12 h (Fig. 2b). Thus, using microscopy-based real-time
visualization of BDQ action, we were able to establish that the
delay in bactericidal activity seen with BDQ was not due to a
heterogeneous response in the bacterial population. In fact, the
entire population uniformly decreased their growth rate (Fig. 2b,
Supplementary Movie 1). Very few cell lysed during the ﬁrst 100 h
of BDQ exposure (Supplementary Fig. 1a). However, after this lag
period a signiﬁcant fraction of cells began to lyse (Supplementary
Fig. 1b). This rate of cell lysis continued even after the drug
washout (from day 17 to 24 (Fig. 2a, Supplementary Fig. 1b)),
with similar kinetics as during the drug exposure, suggesting
strong post-antibiotic killing mediated by BDQ. As an end point
assay we carried out propidium iodide staining to determine the
fraction of intact cells with compromised cell membranes.
Interestingly, we did not observe any regrowth after drug
washout, even though a signiﬁcant number of green ﬂuorescent
protein (GFP)-positive intact cells were found to be propidium
iodide negative (34.8%) (Supplementary Fig. 1b), in line with a
pronounced post-antibiotic effect.
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When M. tuberculosis was exposed to 10-fold lower BDQ
(30 MIC) signiﬁcant lysis (46%) was observed, but interestingly
some of the cells continued to elongate in presence of the drug
(Supplementary Fig. 2, Supplementary Movie 2). This suggests
that either the intracellular concentrations of BDQ in these
bacteria were not sufﬁcient to completely shut down ATP
synthesis or that these bacteria were able to generate enough ATP
using alternate mechanisms to extend their survival.
Global transcriptional response of M. tuberculosis to BDQ.
Insight into the changes in bacterial energy metabolism that assist
in survival under conditions of ATP depletion may provide clues
for the delayed onset of bacterial killing. We examined the global
transcriptional response of mycobacteria to BDQ, focusing on the
changes in the gene expression proﬁle during the initial phase of
treatment (30, 180 and 360min) (Fig. 3a). Genes showing the
strongest upregulation at 30 and 180min time points belong to
the mycobacterial dormancy regulon (Fig. 3a, tables below
panels). We observed a transient induction of all 39 genes of the
dormancy regulon represented in our microarray analysis at 30
and 180min, whereas at 360min the expression proﬁle of this
regulon largely resembled the baseline proﬁle (0min) (Fig. 3b).
This so-called dormancy regulon is a set of 48 genes that are
induced when M. tuberculosis responds to multiple stresses,
including the transition between respiring and nonrespiring
conditions, redox stress or poisoning by nitric oxide20–23.
The dormancy regulon has been associated with metabolic
states requiring less ATP and is postulated to play a role in
sustaining bacterial ATP levels19,23,24. The upregulation of the
dormancy regulon observed here in response to BDQ may act as a
bacterial defence mechanism to countract cellular ATP depletion
and may thus contribute to the temporal delay in bacterial killing.
Transcriptomic data also revealed that genes belonging to the
ATP synthase operon are upregulated (Fig. 3c), presumably
initiated by feedback mechanisms triggered by depletion of
cellular ATP levels. This upregulation probably reﬂects a strategy
to counteract the inhibition of ATP synthase during the initial
phases of BDQ exposure. Upregulation of representative
components of both the dormancy regulon and the ATP synthase
operon was conﬁrmed by quantitative reverse transcriptase real-
time polymerase chain reaction (Supplementary Fig. 3a,b). Apart
from the strong induction of dormancy and ATP synthase genetic
components seen at 30min and 180min time points, transcrip-
tome data at 360min time point revealed moderate upregulation
of the isocitrate lyase (rv0467) and of the cytochrome bd complex
(rv1621c, rv1622c, rv1623c), in addition to proteins of hypothe-
tical function (Fig. 3a). Both isocitrate lyase, a key enzyme of the
glyoxylate pathway, and cytochrome bd, an alternative electron
acceptor in the respiratory chain, are prominent components of
energy metabolic pathways under conditions of physiological
stress, such as during mouse lung infection, in human macro-
phages or in the presence of inhibitors of energy metabolism25–27.
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Figure 1 | Delayed killing of M. tuberculosis by BDQ. (a) Kill kinetics of BDQ for M. tuberculosis over a period of 18 days and (b) initial 5 days of the
BDQ kill kinetics. The bacteria were grown in liquid culture (Middlebrook 7H9 medium) in the presence of the indicated concentrations of BDQ or
the front-line anti-TB drug isoniazid as a control. (c) Decrease of cellular ATP levels in M. tuberculosis during 18 days of BDQ treatment. (d) Cellular
ATP levels during the initial 48 h of BDQ treatment. Inset: cellular ATP levels in the BDQ-resistant M. tuberculosis strain. ATP levels were determined
using the bioluminescence method and are displayed as relative luminescence units (RLUs). Representative results from two experiments are shown.
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In contrast, pronounced downregulation was observed for two
components of the large ribosomal subunit (rv0703 and rv0719,
180min) (Supplementary Data 1). This suggests downregulation
of protein synthesis thereby limiting cellular ATP consumption.
Proteomic response of M. tuberculosis to BDQ. Coupled to our
understanding of the global transcription proﬁle, we performed
quantitative protein analysis onM. tuberculosis treated with BDQ.
Using a mass spectrometric approach with isobaric tagging for
relative quantiﬁcation (iTRAQ)-labelling we identiﬁed a total of
41,500 proteins and determined their differential expression
6 and 24 h after BDQ exposure (10 MIC) (detailed in
Supplementary Data 2–4). For a global overview of key changes in
metabolism upon BDQ exposure proteins displaying high dif-
ferential regulation (top 100 proteins at each time point) were
grouped into functional categories based on the TubercuList
server classiﬁcation28. At both 6 and 24 h time points, BDQ
treatment most prominently affected intermediate metabolism
and respiration (Fig. 4a), reﬂecting the drug’s unique mechanism
of action. Prominent differential regulation was also observed for
proteins involved in cell wall and cell processes, information
pathways and lipid metabolism as well as for conserved
hypothetical proteins (Fig. 4a).
On the basis of these top-line ﬁndings, we subsequently
focused on metabolic pathways connected to synthesis or
consumption of cellular ATP. Proteins belonging to these
metabolic pathways were selected and their differential regulation
was presented in a heat map (Fig. 4b). We regarded proteins
showing an increase or decrease with a fold change (FC)41.5 as
strongly regulated, those with fold change 1.3oFCo1.5 as
moderately regulated and proteins with fold change 1.0oFCo1.3
as not regulated. Components of the ATP synthase complex were
induced, with strong upregulation found for one subunit at 6 h
and for three subunits at 24 h time point (Fig. 4b, left panel),
reﬂecting a strategy to compensate for inhibition of ATP
synthesis. Enzymes of the glycolytic pathway did not display
differential regulation (Fig. 4b, left panel). Two components of
the tricarboxylic acid cycle, 2-oxoglutarate ferredoxin oxidor-
eductase subunit b and aconitate hydratase, were moderately
upregulated at 6 and 24 h time point, respectively (Fig. 4b, left
panel). Moreover, the PdhB subunit of the pyruvate dehydro-
genase complex, an enzyme linking glycolysis with the tricar-
boxylic acid cycle, was strongly upregulated at 24 h of treatment
(Fig. 4b, left panel). Unlike the typical mycobacterial response to
growth arrest, where the tricarboxylic acid cycle is considerably
downregulated29, this central metabolic pathway apparently
remains functional during bacteriostasis triggered by BDQ.
Activity of this central cycle may help to evade BDQ-induced
antibiotic stress by providing precursors for certain essential
biosynthetic processes or by modulating pressure on the
respiratory chain.
The observed usage of alternative electron acceptors such as
cytochrome bd, which was strongly upregulated at both time
points (Fig. 4b, left panel), may assist in maintaining the
respiratory electron ﬂow. Induction of isocitrate lyase and of
phosphoenolpyruvate-carboxykinase indicates a re-routing of
central carbon metabolism in response to BDQ exposure
(Fig. 4b, left panel), which is reminiscent of the redistribution
of carbon ﬂow reported for M. tuberculosis upon lung infection29.
Two components of the stress response, the heat shock protein
Rv0251c and bacterioferritin, were strongly upregulated (Rv0251c
at 6 and 24 h time points, bacterioferritin at 24 h time point)
(Fig. 4b, left panel). Induction was also observed for various other
components of the stress response, for example, moderate
upregulation was found for the co-chaperonin GroES after 24 h
of treatment and for the DnaK protein at both 6 and 24 h time
point (Fig. 4b, left panel). Induction of these facilitators of protein
(re-)folding may contribute towards optimizing the integrity of
synthesized proteins or to recycling of existing proteins.
In contrast, major biosynthetic pathways were generally
found downregulated upon BDQ treatment, including ribosomal
protein synthesis, DNA biosynthesis and synthesis of mycolic
acids, a key component of the mycobacterial cell envelope30
(Fig. 4b, right panel). Strong downregulation was observed for
several polyketide synthases, several ribosomal subunits and for
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Figure 2 | Real-time single-cell analysis of effect of BDQ on
M. tuberculosis. M. tuberculosis expressing GFP was grown in a microﬂuidic
device and imaged over a 24-day period at 1-h intervals. BDQ (300 MIC)
was added to the ﬂow medium between t¼ 76–412 h (days 3–17). (a)
Snapshot images of a representative microcolony imaged on the green
channel are shown. Numbers (upper right) indicate days elapsed. Labels
(upper left) indicate presence or absence of BDQ in the ﬂow medium
(7H9). Scale bar, 5 mm. (b) Single-cell growth rates were determined
by measuring the areas of single cells (n¼ 50) in the 12 h before BDQ
exposure (64–76h) and in the immediate 12 h after BDQ exposure
(76–88h) and ﬁtting exponential curves to the data. Red lines represent
the mean ± 95% conﬁdence intervals. For comparison of growth
rates, P-values were determined using the Kolmogorov–Smirnov
non-parametric test.
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DNA helicase and a ribonucleotide-diphosphate reductase
subunit, which are components of lipid, protein and DNA
biosynthesis, respectively (Fig. 4b, right panel). This suggests that
in response to ATP depletion via inhibition of ATP synthase by
BDQ bacteria try to evade shortage of energy by minimal usage of
ATP consuming processes. To support this observation, we
measured protein and DNA synthesis activity in mycobacteria
grown in presence of BDQ (Supplementary Fig. 4). BDQ blocked
both protein and DNA synthesis in a dose-dependent manner, in
line with the our proteome data.
Taken together, the observed changes in the mycobacterial
proteome reﬂect a general strategy employed by mycobacteria for
preserving ATP pools, minimizing consumption of cellular ATP
and enhancing the capacity of ATP-generating pathways.
Inﬂuence of BDQ on bacterial NADH/NADþ redox balance.
In addition to changes occurring in the transcriptome and
proteome of M. tuberculosis we also assessed the impact of the
drug on bacterial redox balance. We determined the intracellular
ratio of NADH, a central redox cofactor of the bacterial cell,
versus its reduced version NADþ during the initial period of
BDQ exposure. BDQ at 3 or 30 MIC caused elevated cellular
NADH/NADþ ratios within 24 h after drug addition (Fig. 5a),
indicating that the intracellular NADH/NADþ redox balance is
shifted towards a reducing state. This change may be due to
blockage of ATP synthase by BDQ, which likely exerts back
pressure on the mycobacterial respiratory chain, thereby imped-
ing the respiratory electron ﬂow and in turn diminishing rates of
NADH oxidation. Disturbed NADH/NADþ redox balance may
trigger activation of the dormancy regulon via reduction of its
DosS sensor kinase31,32, thereby assisting in adaptation to BDQ-
induced stress.
On the other hand, elevated NADH/NADþ ratios disturb
cellular redox balance and may concomitantly inhibit metabolic
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Figure 3 | Transcriptional response of M. tuberculosis to BDQ treatment. (a) Global gene expression changes 30, 180 and 360min after addition of
BDQ (30 MIC). The volcano plot shows the log2-fold changes in gene expression induced by BDQ as compared with untreated control. The log
odds describe the probability that the gene indeed is differentially expressed, a zero value corresponds to a 50-50 chance of differential expression.
Genes were ranked based on their absolute log2-fold change and the 10 genes with highest differential regulation at each time point (dots highlighted
in red in the volcano plots) are listed below the respective panels. For all listed genes differential regulation was signiﬁcant (Po0.05, determined
using the moderated t-statistics). A list of top 20 regulated genes is presented in Supplementary Data 1. (b,c) Expression of the dormancy regulon
(b) and the ATP synthase operon (c) at 30, 180 and 360min of BDQ treatment. The colour scales represent log2-fold changes in gene expression.
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pathways involved in production of NADH. To validate this
observation, we measured the activity of glyceraldehyde-3-
phosphate dehydrogenase, a central enzyme in the glycolytic
pathway, in a biochemical assay. We found signiﬁcantly lower
activity after 24 h of BDQ treatment as compared with untreated
controls (Fig. 5b).
Impact of energy source for drug susceptibility. On the basis of
the proteome results indicating functional glycolyic pathways and
tricarboxylic acid cycle during the initial phase of BDQ treatment,
we explored the impact of the employed energy source on killing
of M. tuberculosis by BDQ. Fermentable energy sources such as
glycerol or glucose allow for ATP synthesis by glycolysis or by
oxidative phosphorylation using ATP synthase. With fatty acids
as energy source, the bacteria cannot utilize the glycolytic path-
way and ATP production is restricted to oxidative phosphoryla-
tion with ATP synthase. For these reasons mycobacteria using
fatty acids as energy source may display enhanced susceptibility
to BDQ. As depicted in Fig. 6, M. tuberculosis grown on fatty
acids, such as oleic acid, propionic acid or sodium acetate,
displayed accelerated killing by BDQ within the initial days of
treatment as compared with controls grown on glycerol or
glucose. In particular bacteria grown in presence of oleic acid as
energy source yielded enhanced bacterial susceptibility to BDQ
exposure as compared with glycerol as the standard medium
(Po0.05 on 5 of the 7 initial days, determined by t-test). For
propionic acid and sodium acetate the enhancement of killing
was less pronounced (Po0.05 on two days and on one day,
respectively). This ﬁnding has important implications since it has
been proposed that the mycobacterial sub-population residing in
human macrophages primarily utilizes fatty acids as energy
source27,33. Our results may therefore in part explain the strong
bactericidal activity observed for BDQ in mycobacteria-infected
macrophages, where the intracellular potency of BDQ exceeded
its extracellular activity16. Interestingly, for the front-line anti-TB
drugs the killing of M. tuberculosis in lipid-loaded macrophages
was found to be signiﬁcantly reduced34. Thus, inhibitors of
respiratory ATP synthesis may be particularly suitable for the
eradication of this difﬁcult to kill minority sub-population of M.
tuberculosis in the human host cells.
Discussion
Our ﬁndings suggest that exposure of M. tuberculosis to BDQ
triggers metabolic remodelling to counteract ATP depletion.
Bacterial killing is associated with depletion of cellular ATP by
more than 10-fold. In the intial phase of BDQ-induced
bacteriostasis, remodelling of ATP consuming and ATP produ-
cing pathways may enable maintenance of ATP levels sufﬁcient
for bacterial viability for several days and concomitantly prevent
killing. Utilization of the glycolytic pathway may contribute
sufﬁcient ATP for short-term survival, but on continued
inhibition of ATP synthase, this alternative pathway apparently
is not sufﬁcient. It can be speculated that increased cellular
NADH/NADþ ratios cause a decrease in glycolytic rates, thereby
preventing adequate ATP production by glycolysis. In this regard,
factors linking cellular ATP depletion with bacterial death need to
be elucidated to shed light on bacterial killing by inhibitors of
energy metabolism in particular and on the mechanism of killing
by bactericidal antibiotics in general.
It is important to understand if the metabolic response to BDQ
is a non-speciﬁc defence mechanism or is more speciﬁc to this
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antibacterial drug. Cessation of growth, decreased cellular ATP
levels, upregulation of the dormancy regulon as well as down-
regulation of protein and DNA biosynthesis pathways has been
reported for mycobacteria during dormancy19,20,24,35, adaptation
to the macrophage environment25 or upon mouse lung
infection29,36. However, BDQ induces a distinct response in
terms of upregulation of energy metabolic pathways, particularly
the ATP synthase, which is not observed under conditions
of general stress or bacteriostasis29,36,37. Stimulation of the
dormancy regulon, observed here upon inhibition of ATP
synthase by BDQ, apparently does not represent a general
response to inhibition of energy metabolism, as several inhibitors
of respiratory functions, such as chlorpromazine or potassium
cyanide, did not cause signiﬁcant induction of the dormancy
response26. In contrast, increased cytochrome bd expression, as
found here in the presence of BDQ, was previously reported in
response to a broad range of inhibitors of energy metabolism and
in related metabolic stress situtations26,36,38, reﬂecting a more
general role of the cytochrome bd in the transition between
bacterial (energy) metabolic states.
The link between inhibition of ATP synthase by BDQ and the
subsequent induction of the dormancy regulon may be due to
multiple factors, like decreasing cellular ATP levels or changes in
intracellular redox state. Decreasing ATP levels may via unknown
cellular ATP sensors activate the dormancy regulon. ATP sensors
have been reported for several bacterial species39–41 and it can be
speculated that ATP sensing factors, such as members of the
univeral stress protein family42, may be involved in the
mycobacterial response to external stresses inﬂuencing bacterial
ATP levels. Alternatively, a reduced state of the bacterial
respiratory chain, as indicated by the elevated NADH/NADþ
ratios, may activate the DosS sensor kinase, which has been
reported to be a redox sensor31,32. BDQ-triggered induction
of the dormancy regulon is transient with gene expression
essentially returning to baseline level after 6 h. This period is
shorter as compared with dormancy regulon induction by nitric
oxide20; however, a transient nature of dormancy regulon
induction with the majority of genes returning to baseline levels
has been reported previously for M. tuberculosis in a deﬁned
hypoxia model38. The duration of dormancy regulon induction
and the level of gene expresion in the new steady state may
signiﬁcantly depend on the type of stress applied or on the model
system used. In this regard, deﬁning the bacterial regulatory
network related to BDQ-induced metabolic changes, as recently
reported for M. tuberculosis in response to hypoxia and
re-aeration43, may assist in pinpointing key nodes of metabolic
interactions linked to induction and cessation of the dormancy
response.
For new anti-TB drug candidates targeting energy metabolic
pathways using eBA as an efﬁciency surrogate may underestimate
their clinical potency. Apart from BDQ, delayed bactericidal
activity has also been reported for other investigational drugs,
such as PA-824 and delamanid, which likely inhibit multiple
targets including respiratory chain cytochrome oxidases13,44. The
recently discovered drug Q203, which targets the cytochrome bc1
complex of the mycobacterial respiratory chain, was also slow
acting during the ﬁrst 2 weeks of treatment in a mouse model of
acute tuberculosis infection45. This might suggest a general
phenomenon of delayed onset of bactericidal activity for
respiratory inhibitors, including clofazimine that also targets
respiratory chain, which might be due to metabolic remodelling
as revealed here for BDQ. Certain pharmacological and clinical
factors, such as time to steady state, protein binding and
distribution into ﬁbrotic lesions, cavities and granulomas may
affect the effective drug concentrations at the target sites and also
inﬂuence a drug’s initial activity.
The efﬁcacy of drug candidates targeting respiratory ATP
synthesis may be underestimated in in vitro studies employing
standard growth media46,47, which contain glycerol and glucose
as the primary energy sources. The strong bactericidal effect of
BDQ towards bacteria grown on lipids suggests that for
microbiological characterization of new inhibitors targeting
respiratory ATP synthesis fatty acids or related non-fermentable
energy sources might be explored.
In addition, these results highlight the importance of energy
metabolism inhibitors in combating mycobacteria residing in
lipid-rich micro-environments. As such, new drug candidates
targeting ATP synthase and associated metabolic processes are
expected to have potent activity in humans.
Methods
Kill kinetics onM. tuberculosis. M. tuberculosis H37Rv was cultured in 7H9 broth
to mid-log phase. Bacteria were diluted toB106 CFUml 1. BDQ was added at 0.1,
1 and 10mgml 1, isoniazid at 10 mgml 1. At indicated time points, samples were
taken and CFU counts were performed.
Cellular ATP level measurement of M. tuberculosis. M. tuberculosis H37Rv was
cultured in 7H9 broth to mid-log phase. Bacteria were diluted toB106 CFUml 1.
BDQ was added at 0.1, 1 and 10 mgml 1, isoniazid at 10 mgml 1. At indicated
time points, samples were taken, and 1.5ml bacteria suspension was mixed with
3ml boiling Tris-EDTA reagent (100mM Tris, 4mM EDTA, pH 7.75) and mixed
for 2min with glass beads, heated at 100 C for 5min and cooled on ice. Cell debris
was removed by centrifugation. An equal volume of luciferase reagent (ATP
Bioluminescence Assay Kit HS II, Roche) was added to the supernatant and
luminescence was measured. The majority of bacteria at day 18 were not lysed
as determined by microscopy (Fig. 2) but could not be counted on plates (Fig. 1a).
For this reason, ATP levels were expressed per ml of culture23 and not per CFU.
Impact of energy source on efﬁcacy of BDQ on M. tuberculosis. M. tuberculosis
H37Rv was cultured in 7H9 broth to mid-log phase. Bacteria were diluted to
B106 CFUml 1 in Middlebrook 7H9 medium or in Middlebrook medium with,
respectively, 2% glucose, 0.1% propionic acid, 0.01% oleic acid or 0.1% sodium
acetate. Bacteria were adapted to the new media for 24 h. BDQ was added at
1 mgml 1, isoniazid at 10mgml 1. Kill kinetics and cellular ATP levels were
performed daily for 7 days.
Time-lapse imaging. For purposes of imaging, M. tuberculosis expressing GFP
was constructed by transforming with the attB-integrating vector pND235
(Wakamoto et al.48). Cells were grown in 7H9 medium at 37 C to mid-log phase
and were seeded into a custom-made microﬂuidic device as described before48.
Brieﬂy, bacteria from mid-exponential cultures were concentrated 10-fold by
centrifugation and were passed through a 5 mm ﬁlter (Millipore) to get rid of
clumps. 2 ml of these ﬁltered bacteria were sandwiched between the coverslip and
a cellulose membrane, on top of which the microﬂuidic device was placed. This
whole assembly was secured in a custom-built acrylic frame and placed on the
microscope stage for imaging48. The inlet tube connected to the microﬂuidic device
was connected to a syringe containing fresh 7H9 medium and the outlet tubing was
directed to the waste receptacle. Medium (with or without drug) was replaced every
20 h. Medium was pumped through the syringe pump at a ﬂow rate of
25 ml min 1. Images were acquired at 1 h intervals on the phase and FITC
(excitation 490/20; emission 528/38) channels using a DeltaVision personalDV
imaging system (Applied Precision) equipped with a  100 objective (Olympus
UPLFL 100X PH, 1.3 NA) and a CoolSnap HQ2 camera. As an end point assay,
1.0 mgml 1 propidium iodide was added to the ﬂow medium for 24 h to stain cells
with permeabilized cell envelopes and imaging done on the red channel (excitation
555/28; emission 617/73).
Analysis of the time-lapse image stacks was carried out using ImageJ v 1.47a
(http://rsb.info.nih.gov/ij/). Area of individual cells was measured using the
polygon function and single-cell growth rates were calculated by ﬁtting the curves
with exponential growth function. The survival curves depicted in Supplementary
Fig. 1 and Supplementary Fig. 2 were generated by tracking cell division and lysis
events over the course of the experiment using the ‘Cell Counter’ plugin of ImageJ.
Cytolysis was scored visually by abrupt loss of GFP ﬂuorescence and abrupt
decrease in phase intensity.
Statistic analysis and ﬁtting of data was performed using Prism (GraphPad).
For comparison of growth rates, P-values were determined using the
Kolmogorov–Smirnov non-parametric test.
Transcriptome analysis. For RNA isolation, M. tuberculosis H37Rv was cultured
in 7H9 broth to mid-log phase. BDQ was added at ﬁnal concentration of 1 mM.
At 0.5, 1, 3 and 6 h after addition of the compound, 10ml of culture was pelleted
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms4369
8 NATURE COMMUNICATIONS | 5:3369 | DOI: 10.1038/ncomms4369 | www.nature.com/naturecommunications
& 2014 Macmillan Publishers Limited. All rights reserved.
and resuspended in 1ml of RNAprotect Bacteria Reagent. Bacteria were pelleted again,
resuspended in RLT-buffer with b-mercaptoethanol and mechanically disrupted
with Mixer Mill MM 310. Only the supernatant was used for RNA extraction using
RNeasy Protect Bacteria Mini kit (Qiagen). RNA was eluted in RNAse free water.
Four biological replicates were used to extract RNA from M. tuberculosis cultures.
For the 1 h time point the RNA quality and RNA yield was affected, possibly due to
effects of the compound on the bacteria. As the resulting array data for the 1 h
time point were inconclusive, they were not taken into consideration for the
interpretation, but included in the data submission to the GEO repository.
For labelled cDNA preparation, reverse transcription was performed on 5 mg
of total RNA using random primers and Superscript II RT (Invitrogen Life
Technologies). For the reaction, 750 ng random hexamers were mixed with the
RNA in a total volume of 30 ml and heated to 70 C for 10min. After cooling to
25 C for 10min, the ﬁrst strand reagents were added and incubated for 1 h at 37 C
followed by 1 h at 42 C. SuperScript II was heat inactivated at 70 C for 15min and
the mixture cooled to 4 C. The template RNA was removed using RNase H
(Invitrogen) and RNase A/T1 cocktail (Ambion) at 37 C for 20min in 100 ml total
volume. The cDNA was puriﬁed using the QiaQuick PCR puriﬁcation kit
from Qiagen. The puriﬁed cDNA was than fragmented using DNAse I in 1
One-Phor-All buffer (GE Healthcare) for 20min. If the bulk of DNA was not at
50–100 bp, the digest was repeated. After fragmentation a 30-end terminal labelling
was performed for 2 h at 37 C using the BioArray Terminal Labeling Kit with
Biotin-ddUTP, (ENZO Diagnostics, Farmingdale, NY P/N 900181). The
fragmented and end-labelled cDNA was added to the hybridization solution.
For microarray analysis, samples were processed on TB_ALL GeneChips with
antisense probes (Affymetrix, Santa Clara, CA, part # 510285) containing B6,000
probe sets interrogating 3,924 ORFs and 738 intergenic regions of M. tuberculosis
H37Rv. For hybridization, staining and scanning the Affymetrix E. coli Antisense
Genome Array protocol was followed. Hybridization was performed for 18 h
at 45 C under continuous rotation according to the recommendations of
Affymetrix. Arrays were stained in Affymetrix Fluidics stations using Streptavidin/
Phycoerythrin followed by staining with anti-streptavidin antibody and a second
Streptavidin/Phycoerythrin staining. Subsequently, arrays were scanned with a
Genechip scanner. All data analysis was done in R (version 2.14.1) using
BioConductor packages (version 2.9). Data preprocessing was done with no
background correction, vsn normalization and summarization using median
polish. Differential gene expression was calculated using the BioConductor package
limma49 (http://www.bioconductor.org/packages/release/bioc/vignettes/limma/
inst/doc/usersguide.pdf), with default settings. Log odd values were automatically
adjusted for multiple testing.
For reverse transcription quantitative PCR, ﬁrst strand cDNA synthesis was
performed on 0.5 mg total RNA using random hexamer primers and Superscript II
RT (Invitrogen Life Technologies). TaqMan FAM and TAMRA probes
(Eurogentec) and primers for the mycobacterial genes were designed using the
Primer Express software (version 2.0.0, Applied Biosystems); a list of primers
provided as Supplementary Table 1. Ampliﬁcation of endogenous 16S ribosomal
RNA was performed to standardize the amount of cDNA sample added to each
reaction. Real-time quantiﬁcation was carried out using the ABI PRISM 7900HT
Sequence Detection System (Applied Biosystems) as described by the manufac-
turer. Serial dilutions of various cDNAs were used to generate standard curves of
threshold cycles versus the logarithms of concentration for 16S ribosomal RNA and
the genes of interest. A linear regression line calculated from the standard curves
allowed determination of transcript levels in the RNA samples by the relative
quantiﬁcation method.
Proteome analysis. For sample collection, M. tuberculosis H37Rv was cultured in
7H9 broth to mid-log phase. BDQ was added at ﬁnal concentration of 1 and 10
MIC and isoniazid at 1 MIC. After 6 and 24 h after addition of the compound,
50ml of culture (one biological replicate) was washed with PBS and pelleted.
Bacteria were heat-killed and resuspended in 2ml lysis buffer (8.9M urea, 2%
Triton X-100, 2% IPG-buffer (Roche), 0.13M DTT, 8mM PMSF). The lysate was
passed three times through the French Press at 14,000 Psi in a small cell. Cell debris
was removed by centrifugation and supernatant was collected.
For protein digestion, the proteins were cleaned up from the cell lysis buffer by
cold ethanol/acetone precipitation. The pellets were resuspended in 6M urea,
2M thiourea, 50mM triethyl ammonium bicarbonate (TEAB), pH 8.0. The
proteins were reduced with 20mM dithiothreitol for 1 h at 30 C followed by
alkylation with 50mM iodoacetamide for 30min in the dark. The samples were
diluted 1:8 with 50mM TEAB, pH 8.0 and digested with trypsin over night at room
temperature. After digestion the samples were acidiﬁed to a ﬁnal concentration
of 2% formic acid and centrifuged at 12,000 g for 10min to precipitate the lipids.
Before iTRAQ labelling, the supernatants were desalted and dried down using
vacuum centrifugation.
For iTRAQ labelling, the peptides were resuspended in 200mM TEAB, pH 8.0.
A total of 100 mg forM. tuberculosis H37Rv and 50 mg for the other conditions were
labelled (H37Rv BDQ 1 MIC 6þ 24 h; H37Rv BDQ 10 MIC 6þ 24 h and
H37Rv isoniazid 1 MIC 6þ 24 h) with 4-plex iTRAQ (Applied Biosystems,
Foster City, CA). The labelling was performed as described by the manufacturer.
After labelling, the samples were mixed 1:1:1:1 and dried down using vacuum
centrifugation.
For nano-LC MS/MS, the peptide mixtures were fractionated by loading 20 mg
samples on a HPLC Agilent 1200 system with a homemade TSKGel Amide-80
HILIC column. The peptides were eluted with an inverse gradient from 100% B
(90% ACN; 0.1% TFA) to 60% B in 30min with an increasing amount of A-solvent
(0.1% TFA). The HILIC fractions were further analysed by an EASY nano-HPLC
system (Thermo Fischer Scientiﬁc) connected to an LTQ OrbiTrap XL mass
spectrometer (Thermo Fisher Scientiﬁc). The nano-HPLC system was equipped
with a self-packed 15-cm analytical column (100 mm ID, 360 mm OD, ReproSil-Pur
C18 AQ 3 mm; Dr Maisch, Germany). The mass spectrometer was operated in
positive ion mode and a data-dependent acquisition method that automatically
switched between MS and MS/MS was employed. The most three intense ions from
the MS spectra were fragmented by collision induced dissociation in the LTQ and
additionally fragmented by high-energy collision induced dissociation (HCD) with
detection in the OrbiTrap analyser. The HCD fragmentation is necessary to obtain
abundant iTRAQ reporter ions for later quantitation.
The raw MS/MS data were analysed using Proteome Discoverer v1.3 beta
(Thermo Scientiﬁc). MS/MS spectra were converted to .mgf ﬁles and searched
against the NCBI database (taxonomy: Mycobacterium tuberculosis H37Rv).
Database search was performed with the following ﬁxed parameters: precursor
mass tolerance 10 p.p.m.; MS/MS mass tolerance 0.8Da for collision induced
dissociation data or 0.05Da for HCD data and trypsin as protease with up to two
missed cleavages. Variable modiﬁcations included: methionine oxidation and
N-terminal and lysine 4-plex iTRAQ label. A concatenated decoy database search
was performed, which was derived from the NCBIM. tuberculosis H37Rv database.
Peptides with a FDR of 5% and an ion score of 20 (MudPit scoring) and Rank 1
were accepted. Protein identiﬁcations were accepted when minimum two peptides/
protein were identiﬁed and the protein had a score of 30 or higher. iTRAQ
quantiﬁcation was performed using Proteome Discoverer with reporter ion
integration within a 50 p.p.m. window. The quantiﬁcation was based on a relative
quantiﬁcation, means the intensities from the reporter ions from every condition
(wild type H37Rv BDQ 1 MIC 6þ 24 h; wild type H37Rv BDQ 10 MIC
6þ 24 h and wild type H37Rv isoniazid 1 MIC 6þ 24 h) were compared with
the intensity of the reporter ion of the wild type H37Rv (control). The intensities of
the reporter ion from the certain conditions were divided by the reporter ion
intensity from the wild type H37Rv to obtain a peptide ratio for every identiﬁed
peptide. The protein ratios were than calculated based on the peptide ratios of the
individual proteins. The peptide ratios were log2 transformed and normalized
against the median. The protein ratios (fold change) were than calculated based on
the peptide ratios of the individual proteins. Strongly regulated proteins were
determined based on the 1.5-fold change and moderately regulated proteins with a
1.3-fold change, a cutoff often chosen for biological signiﬁcance50.
Glyceraldehyde-3-phosphate dehydrogenase assay. M. tuberculosis was
cultured in 7H9 broth and grown to an A600 nm of 0.8. Cultures were treated with
0.1, 1 or 10mgml 1 BDQ for 6 and 24 h. Control cultures were treated with
dimethylsulphoxide. Culture aliquots (10ml) were harvested and resuspended in
cell lysis buffer—50mM Tris pH 8.0, 10% glycerol, containing protease inhibitor
cocktail (Roche, Switzerland). Cell lysis was carried out by bead-beating using
0.1mm zirconia beads in a Precellys-24 homogenizer (Biolabo, Switzerland).
Glyceraldehyde-3-phosphate dehydrogenase activity was measured in whole cell
protein extracts by following NADH formation measuring absorbance at 340 nm,
as per the procedure described previously51. Assay was performed at 37 C in
200 ml of assay buffer comprising 0.015M sodium pyrophosphate buffer pH 8.5,
0.03M sodium arsenate, 2.5mM NADþ , 2.5mM glyceraldehyde-3-phosphate.
The assay mixture (without the substrate) was mixed with 10 mg of protein extract
and shaken at 37 C to equilibrate the temperature. The reaction was initiated by
addition of the substrate, glyceraldehyde-3-phosphate. Controls included wells
without protein extract or without the substrate. Puriﬁed NADH (Sigma) was used
to generate calibration curves. One unit is deﬁned as the quantity of enzyme
reducing 1 mmol NADþ min 1mg 1 of protein extract.
NADH/NADþ assay. M. tuberculosis was cultured in 7H9 broth and grown to an
A600 nm of 0.8. Cultures were treated with 0.1, 1 or 10 mgml 1 BDQ for 24 h.
NADH and NADþ concentrations were determined and the NADH/NADþ ratio
was calculated as described52. Brieﬂy, bacteria were harvested, resuspended in
0.2M HCl (for NADþ extraction) or in 0.2M NaOH (for NADH extraction),
heated at 55 C for 10min and cooled on ice. Cell debris was removed by
centrifugation. The supernatant was preincubated for 5min in the dark in
Bicine buffer containing EDTA, ethanol, 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT), and phenazine ethosulfate. The reaction
was started by addition of yeast alcohol dehydrogenase II and the absorbance at
570 nm was recorded for 10min.
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